Shopping Cart
- Remove All
- Your shopping cart is currently empty
LGD-2226 is a selective and orally active androgen receptor modulator (EC50: 0.2 nM, Ki: 1.5 nM for the human androgen receptor). LGD-2226 can be used for muscle wasting, osteoporosis, and sexual dysfunction.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
25 mg | $1,520 | 6-8 weeks | |
50 mg | $1,980 | 6-8 weeks | |
100 mg | $2,500 | 6-8 weeks |
Description | LGD-2226 is a selective and orally active androgen receptor modulator (EC50: 0.2 nM, Ki: 1.5 nM for the human androgen receptor). LGD-2226 can be used for muscle wasting, osteoporosis, and sexual dysfunction. |
Targets&IC50 | Androgen receptor:(EC50)0.2 nM, Androgen receptor:(ki)1.5 nM |
In vitro | LGD-2226 occupies the same binding pocket as dihydrotestosterone (DHT), the protein backbone is superposable to that observed with DHT. The trifluoroethyl groups of LGD-2226 occupy the same space in the receptor as the C and D rings of the steroid. GLN711 forms an additional hydrogen bond with the quinolone NH of LGD-2226. Just like the carbonyl group of DHT, the quinolone carbonyl forms hydrogen bond interactions with GLN711 and ARG752 [1]. |
In vivo | LGD-2226 has weak trophic effects on the prostate. LGD-2226 (100 mg/kg) treatment, is required to maintain prostate weight at intact levels. LGD-2226 (1-100 mg/kg; p.o.; daily; for 2 weeks; adult oORDX rats) has a pronounced effect on the levator ani muscle, maintaining the muscle weight at the eugonadal levels at an approximate 3 mg/kg dose. These data clearly show the tissue selectivity of LGD-2226[1]. |
Molecular Weight | 392.22 |
Formula | C14H9F9N2O |
Cas No. | 328947-93-9 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.